Your browser doesn't support javascript.
loading
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger, Frédérique; Marce, Margaux; Delaloge, Suzette; Hardy-Bessard, Anne-Claire; Bachelot, Thomas; Bièche, Ivan; Pradines, Anne; De La Motte Rouge, Thibault; Canon, Jean-Luc; André, Fabrice; Arnould, Laurent; Clatot, Florian; Lemonnier, Jérôme; Marques, Sandrine; Bidard, François-Clement.
Afiliación
  • Berger F; Biometry Unit, Institut Curie, PSL Research University, Paris and Saint-Cloud, France.
  • Marce M; Biometry Unit, Data Center, Institut Régional du Cancer de Montpellier, Montpellier, France.
  • Delaloge S; Breast Oncology Department, Gustave Roussy, Villejuif, France.
  • Hardy-Bessard AC; Dapartment of Medical Oncology, Centre Armoricaind'Oncologie, Plérin, France.
  • Bachelot T; Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
  • Bièche I; Pharmacogenomic Unit, Genetics laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, Paris, France.
  • Pradines A; INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, Toulouse, France.
  • De La Motte Rouge T; Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.
  • Canon JL; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • André F; Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgique.
  • Arnould L; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Clatot F; Department of Pathology, Centre Georges François Leclerc, Dijon, France.
  • Lemonnier J; Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.
  • Marques S; Research and Development Department, UNICANCER, Paris, France.
  • Bidard FC; Research and Development Department, UNICANCER, Paris, France.
BMJ Open ; 12(3): e055821, 2022 Mar 03.
Article en En | MEDLINE | ID: mdl-35241469
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / ADN Tumoral Circulante Tipo de estudio: Clinical_trials Aspecto: Ethics Límite: Female / Humans Idioma: En Revista: BMJ Open Año: 2022 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / ADN Tumoral Circulante Tipo de estudio: Clinical_trials Aspecto: Ethics Límite: Female / Humans Idioma: En Revista: BMJ Open Año: 2022 Tipo del documento: Article País de afiliación: Francia